Aktuellt
SENASTE
Redeye comments on Fluoguide providing an update on its clinical trial progress. Updated timeline guidance mostly aligns with our expectations, except for a delay of phase IIa HNSCC top-line data to H2 2023e versus our previous estimate of mid-2023e. Considering promising interim data and the HNSCC delay relating to a trial expansion, our view of Fluoguide’s investment case remains essentially unchanged.
LÄS MER
